Back
IBBIS Calls for Biosecurity Provisions in EU Biotech Act
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: International Biosecurity and Biosafety Initiative
Relevant to biosecurity governance efforts; illustrates how organizations are pushing to embed biosecurity safeguards into emerging biotech legislation, a domain adjacent to AI biosecurity risk discussions.
Metadata
Importance: 42/100press releasenews
Summary
IBBIS (International Biosecurity and Biosafety Initiative for Science) advocates for the inclusion of robust biosecurity provisions in the EU Biotechnology Act, specifically calling for mandatory DNA synthesis screening and alignment with international biosecurity standards. The organization argues that as biotechnology regulation advances in Europe, biosecurity safeguards must be integrated to prevent misuse of synthetic biology tools. This represents an effort to embed biosecurity norms into emerging biotech regulatory frameworks.
Key Points
- •IBBIS urges the EU to include mandatory synthesis screening requirements in the EU Biotech Act to prevent dangerous biological agents from being ordered.
- •The call emphasizes alignment with international biosecurity standards to ensure consistent global safeguards in the synthetic biology sector.
- •Biosecurity provisions are framed as essential components of responsible biotech governance, not merely optional add-ons.
- •The advocacy reflects growing recognition that DNA synthesis technology poses dual-use risks requiring regulatory attention at the legislative level.
- •IBBIS positions this as an opportunity to set a global precedent for integrating biosecurity into biotech innovation policy.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| IBBIS (International Biosecurity and Biosafety Initiative for Science) | Organization | 60.0 |
Cached Content Preview
HTTP 200Fetched Apr 9, 20264 KB
IBBIS calls for synthesis screening and international standards in EU Biotech Act - IBBIS
About
People
Careers
News
Our Work
Commec Sequence Screening
Customer Screening
Global Synthesis Map
International Standards
Sequence Biosecurity Standards
Vulnerability Disclosure
Contact
About
People
Careers
News
Our Work
Commec Sequence Screening
Customer Screening
Global Synthesis Map
International Standards
Sequence Biosecurity Standards
Vulnerability Disclosure
Contact
IBBIS calls for synthesis screening and international standards in EU Biotech Act
The International Biosecurity and Biosafety Initiative for Science (IBBIS) has submitted its official response to the European Commission’s call for evidence on the forthcoming EU Biotech Act , urging decisive action to embed robust biosecurity measures, harmonised standards, and international coordination into Europe’s biotechnology future.
The EU Biotech Act aims to foster a supportive environment for biotechnology innovation across the continent—helping translate scientific breakthroughs into real-world applications while upholding the highest safety standards. IBBIS welcomes this ambition and stresses that the security of the bioeconomy must be treated as a foundational enabler of innovation, not an afterthought.
Drawing on findings from the ongoing IBBIS Global DNA Synthesis Map , the submission reveals that only 15% of synthetic DNA providers currently implement screening for sequences of concern , a major regulatory and security gap. IBBIS highlights that screening is already required under EU export controls but remains inconsistently applied due to fragmented policy and lack of enforceable standards.
IBBIS is calling on the EU to:
Strengthen and clarify DNA synthesis screening standards, including through enhancements to ISO 20688-2:2024
Support voluntary certification schemes as a transitional tool towards enforceable norms
Incentivize compliance through EU funding and procurement mechanisms
Phase in mandatory standards aligned with international efforts in the U.S. and U.K.
Establish a European Biorisk Expert Group to monitor emerging biosecurity challenges
Introduce biosecurity conditionality into EU research and innovation programmes
“Without a harmonised framework, responsible companies face competitive disadvantages and policymakers face blind spots. It’s time for the EU to lead in setting global norms for secure, responsible biotechnology,” said IBBIS Executive Director Dr. Piers Millet. “The Biotech Act offers a unique opportunity to ensure safety and innovation grow hand-in-hand.”
The IBBIS submission is endorsed by leading global stakeholders, including the International Gene Synthesis Consortium (IGSC) , the European Synthe
... (truncated, 4 KB total)Resource ID:
dd2bc9975c81ec33 | Stable ID: sid_ry80VTCLCq